Antiviral Efficacy and Toxicity of Ribavirin and Foscarnet Each Given Alone or in Combination in the Murine AIDS Model
- 1 March 1997
- journal article
- research article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 143 (1), 140-151
- https://doi.org/10.1006/taap.1996.8080
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Drug Sensitivity of Human Immunodeficiency Virus Type 1 Isolates after Ribavirin TherapyThe Journal of Infectious Diseases, 1997
- In VivoToxicity of Foscarnet and Zidovudine Given Alone or in CombinationToxicology and Applied Pharmacology, 1996
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Tracking HIV during disease progressionCurrent Opinion in Immunology, 1994
- A Randomized Pilot Study of Alternating or Simultaneous Zidovudine and Didanosine Therapy in Patients with Symptomatic Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1994
- Lack of suppression by ribavirin of HIV viraemiaThe Lancet, 1992
- FoscarnetDrugs, 1991
- Tubulointerstitial nephritis caused by the antiviral agent foscarnetTransplant International, 1989
- Foscarnet Nephrotoxicity: Mechanism, Incidence and PreventionAmerican Journal of Nephrology, 1989